VERU Veru Inc. Stock Quote

VERU [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	19.49%	Shs Outstand	80.05M	Perf Week	-4.11%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	60.00M	Perf Month	6.30%
Income	-27.50M	PEG	-	EPS next Q	-0.18	Inst Own	28.70%	Short Float	27.86%	Perf Quarter	129.52%
Sales	60.50M	P/S	16.73	EPS this Y	131.00%	Inst Trans	-2.61%	Short Ratio	0.72	Perf Half Y	65.12%
Book/sh	1.70	P/B	7.55	EPS next Y	-27.30%	ROA	-15.70%	Target Price	34.00	Perf Year	45.30%
Cash/sh	1.42	P/C	9.04	EPS next 5Y	-	ROE	-18.60%	52W Range	4.34 - 17.50	Perf YTD	117.83%
Dividend	-	P/FCF	-	EPS past 5Y	49.20%	ROI	9.80%	52W High	-26.69%	Beta	-0.57
Dividend %	-	Quick Ratio	6.30	Sales past 5Y	22.60%	Gross Margin	81.40%	52W Low	195.62%	ATR	1.83
Employees	252	Current Ratio	6.60	Sales Q/Q	-2.30%	Oper. Margin	-35.60%	RSI (14)	55.26	Volatility	11.78% 17.14%
Optionable	Yes	Debt/Eq	0.11	EPS Q/Q	-367.80%	Profit Margin	-45.60%	Rel Volume	0.26	Prev Close	12.64
Shortable	Yes	LT Debt/Eq	0.08	Earnings	May 24 BMO	Payout	-	Avg Volume	23.08M	Price	12.83
Recom	1.60	SMA20	12.92%	SMA50	34.92%	SMA200	66.18%	Volume	6,067,257	Change	1.50%

Apr-13-21

Initiated

Jefferies

Buy

$19

Feb-09-21

Reiterated

H.C. Wainwright

Buy

$12 → $17

Jan-21-20

Reiterated

H.C. Wainwright

Buy

$4.50 → $6

Mar-20-19

Initiated

Oppenheimer

Outperform

Jul-03-18

Initiated

Maxim Group

Buy

May-25-22 08:30AM	Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022 GlobeNewswire
May-18-22 08:30AM	Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients GlobeNewswire
May-17-22 12:37PM	Catch Fast-Moving Veru Stock as Covid-19 Drug Results Show Promise InvestorPlace +15.56%
08:30AM	Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022 GlobeNewswire
May-16-22 01:26PM	Veru: EUA for Covid-19 Treatment Could Be Granted by Q3, Says Oppenheimer TipRanks
May-13-22 12:45PM	Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry? Simply Wall St. +43.96%
10:08AM	BioMed Stocks On the Move: Nova Mentis, PolarityTE, Veru, and PharmaDrug; Life Sciences Leaders Report Latest Advances in Regenerative Tissue Technology, Novel Therapeutics for Oncology, COVID, Glaucoma, and Autism GlobeNewswire
May-12-22 07:45AM	Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates Zacks +10.66%
06:30AM	Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization GlobeNewswire
May-11-22 08:23AM	Why Veru Shares Are Soaring Today Premarket Benzinga
06:40AM	Veru stock soars after FDA agrees COVID-19 treatment can be submitted for EUA application MarketWatch
06:30AM	FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients GlobeNewswire
May-10-22 04:32PM	10 Most Anticipated Quarterly Earnings Releases to Watch Insider Monkey
May-09-22 09:30AM	Veru Stock Could Face Difficulties If the Culper Research Report Is True InvestorPlace
May-05-22 06:15PM	Veru Inc. (VERU) Stock Moves -1.8%: What You Should Know Zacks
03:00PM	Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline Zacks
May-04-22 10:53AM	BioMed Momentum: NMLSF, BBI, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for Autism, COVID-19, Oncology, and Glaucoma GlobeNewswire +6.08%
May-02-22 05:33PM	Why Veru Stock Plummeted on Monday Motley Fool -12.37%
08:30AM	FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study GlobeNewswire
Apr-28-22 08:30AM	Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th GlobeNewswire -8.84%
Apr-26-22 10:46AM	BioMed Momentum: AGRX, NMLSF, LMLLF, VERU; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Oncology, Glaucoma, and Autism GlobeNewswire -6.67%
Apr-25-22 08:30AM	Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases GlobeNewswire +25.78%
Apr-21-22 07:55AM	Is Veru Stock a Buy Now? Motley Fool
Apr-16-22 06:30AM	This Hidden Stock Exploded by 190% in a Day. Is It a Buy? Motley Fool
Apr-14-22 09:57AM	BioMed Momentum: VERU, NMLSF, PHRX, CRXT; Life Sciences Leaders Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism GlobeNewswire
08:50AM	Here's What Could Help Veru Inc. (VERU) Maintain Its Recent Price Strength Zacks
Apr-13-22 05:36PM	Why Veru Stock Soared Today Motley Fool +42.86%
02:39PM	Veru Stock Could Hit $36, Says Oppenheimer TipRanks
11:49AM	Here's What Veru Inc.'s (NASDAQ:VERU) Shareholder Ownership Structure Looks Like Simply Wall St.
Apr-12-22 04:07PM	Why Veru's Shares Fell 21.8% on Tuesday Motley Fool -18.49%
03:35PM	An experimental COVID drug was so successful that theyre shutting down trials early Fortune
10:21AM	Veru Stock Soars, Retreats After Impressive Data From Covid Treatment Trial TheStreet.com
06:13AM	Stocks Mixed, Inflation Surge, Veru, Cisco And Starbucks - 5 Things You Must Know TheStreet.com
Apr-11-22 11:03PM	10 Stocks Making Headlines on Monday Insider Monkey +182.30%
05:48PM	Why Veru Stock Skyrocketed Today Motley Fool
03:49PM	Pair of Drugmakers Soar in Meme-Like Session on Study Results Bloomberg
01:33PM	Veru's stock nearly triples after oral COVID-19 treatment leads to 'statistically meaningful' reduction in deaths MarketWatch
01:08PM	Fauci warns: Dont pooh-pooh COVID because of low hospitalizations, as new daily cases and deaths extend increases MarketWatch
10:41AM	Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism GlobeNewswire
07:57AM	Midday Stock Movers: Hoth Therapeutics and Veru Soar Investing.com
06:30AM	Verus Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy GlobeNewswire
04:05AM	Twitter, Apple, Nio Fall Premarket; Veru, Sailpoint Soar Investing.com
Mar-04-22 08:30AM	Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference GlobeNewswire
Mar-01-22 08:30AM	Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022 GlobeNewswire
Feb-17-22 08:30AM	Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium GlobeNewswire
Feb-14-22 08:30AM	Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned GlobeNewswire
Feb-12-22 08:30AM	News Flash: 4 Analysts Think Veru Inc. (NASDAQ:VERU) Earnings Are Under Threat Simply Wall St.
Feb-09-22 07:45AM	Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates Zacks +6.19%
06:30AM	Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27% GlobeNewswire
Feb-08-22 10:00AM	Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect? Zacks
Feb-02-22 03:01PM	Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to Decline Zacks
Feb-01-22 08:30AM	Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial GlobeNewswire +6.35%
Jan-31-22 08:30AM	Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome GlobeNewswire +9.70%
Jan-26-22 08:30AM	Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9th GlobeNewswire
Jan-12-22 11:39AM	Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug Zacks
Jan-11-22 06:55PM	Why Veru Stock Triumphed on Tuesday Motley Fool +20.04%
09:15AM	OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates Zacks
Jan-10-22 08:30AM	Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer GlobeNewswire
Jan-03-22 08:30AM	Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022 GlobeNewswire +5.43%
Dec-16-21 06:38PM	AWM Investment Company, Inc. Buys Destination XL Group Inc, LiqTech International Inc, Gambling. ... GuruFocus.com
Dec-14-21 12:38AM	AWM Investment Company, Inc. Buys Destination XL Group Inc, LiqTech International Inc, Gambling. ... GuruFocus.com
Dec-13-21 01:49PM	Gateway at Wynwood Class A office substantially complete, open for more tenants American City Business Journals
08:30AM	Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia GlobeNewswire
Dec-08-21 08:00AM	Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium GlobeNewswire +6.30%
Dec-02-21 10:20AM	Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates Zacks
06:30AM	Veru Reports Record Fiscal 2021 Full-Year Financial Results GlobeNewswire
Nov-25-21 03:00PM	Analysts Estimate Veru Inc. (VERU) to Report a Decline in Earnings: What to Look Out for Zacks
Nov-22-21 11:02AM	Is Veru (NASDAQ:VERU) Using Debt In A Risky Way? Simply Wall St.
Nov-18-21 08:30AM	Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd GlobeNewswire -6.11%
08:00AM	Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500 GlobeNewswire
Nov-08-21 08:30AM	Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021 GlobeNewswire
Oct-13-21 08:30AM	Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer GlobeNewswire
Sep-21-21 12:08PM	What Is The Ownership Structure Like For Veru Inc. (NASDAQ:VERU)? Simply Wall St.
Sep-20-21 08:30AM	Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress GlobeNewswire -5.37%
Sep-09-21 08:30AM	Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress GlobeNewswire
Sep-08-21 08:30AM	Veru to Present at Three Upcoming Healthcare Investment Conferences GlobeNewswire
Sep-02-21 03:44PM	Why Veru Stock Vaulted Higher Today Motley Fool +11.02%
Aug-27-21 04:25PM	Why Veru Stock Blasted Higher on Friday Motley Fool +13.91%
Aug-24-21 03:53PM	Investing in These 3 Stocks Could Double Your Money, Says Oppenheimer TipRanks
Aug-12-21 07:55AM	Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.90%
06:30AM	Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 Third Quarter GlobeNewswire
Aug-05-21 03:01PM	Earnings Preview: Veru Inc. (VERU) Q3 Earnings Expected to Decline Zacks
Jul-29-21 08:30AM	Veru to Report Fiscal 2021 Third-Quarter Financial Results, Host Conference Call on August 12th GlobeNewswire
Jul-23-21 08:06AM	Can You Imagine How Elated Veru's (NASDAQ:VERU) Shareholders Feel About Its 455% Share Price Gain? Simply Wall St.
Jul-16-21 09:05AM	Veru Is Pointed Lower Now TheStreet.com
Jun-28-21 08:30AM	Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress GlobeNewswire +6.23%
Jun-25-21 08:30AM	Veru Enrolls First Patient in Phase 3 VERACITY Clinical Trial of Sabizabulin (VERU-111) in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer GlobeNewswire
Jun-10-21 08:30AM	Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive Advanced Prostate Cancer GlobeNewswire
Jun-08-21 09:13AM	These 4 Measures Indicate That Veru (NASDAQ:VERU) Is Using Debt Reasonably Well Simply Wall St.
Jun-07-21 10:35AM	Veru's Enobosarm Efficacy Correlates with Androgen Receptor Levels in Metastatic Breast Cancer Patients Benzinga
08:30AM	Veru Announces Positive Phase 2 Clinical Data: Efficacy of Enobosarm Therapy Correlates with Androgen Receptor Levels in AR+ER+HER2- Metastatic Breast Cancer Presented at the 2021 ASCO Annual Meeting GlobeNewswire
08:15AM	Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual Meeting GlobeNewswire
May-25-21 08:30AM	Veru to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-24-21 08:30AM	Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting GlobeNewswire
May-19-21 12:55PM	Veru Starts Enrollment In Late-Stage Sabizabulin Trial For COVID-19 Benzinga
08:30AM	Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients GlobeNewswire
May-12-21 10:31AM	Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:30AM	Veru Reports Strong Second-Quarter Financial Results Based on Record High FC2 Prescription Revenues GlobeNewswire
06:15AM	Veru, Inc. to Host Earnings Call ACCESSWIRE
May-10-21 10:46AM	Why Veru (VERU) Might Surprise This Earnings Season Zacks -5.38%

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lu Lucy	Director	Aug 17	Buy	6.78	4,800	32,542	9,800	Aug 19 01:02 PM
FISCH HARRY	Director	Jun 16	Sale	8.35	100,000	835,300	764,025	Jun 21 12:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience